SCHEMBL232284

SCHEMBL232284

COc1ccc(Sc2ccccc2C(=O)O)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
CHEK1 O14757 1/20 0.49
PIM1 P11309 1/20 0.49
MAPK8 P45983 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
HTR1A P08908 1/20 0.48
HTR3A P46098 1/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
SIRT1 Q96EB6 1/20 0.47
NSD2 O96028 1/20 0.47
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA4 P22748 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8533409 0.87 CLCN2 (0.46) HTTMEN1KMT2ASIRT1NSD2
SCHEMBL6216437 0.87 NSD2 (0.44) HTTSIRT1NSD2KDM4EALDH1A1
SCHEMBL11442238 0.84 SIRT1 (0.46) HTTKMT2ASIRT1NSD2KDM4E
SCHEMBL21155022 0.81 HPGD (0.49) HTTMAPK8MEN1KMT2AKDM4E
SCHEMBL315581 0.80 NPC1 (0.59) HTTMEN1KMT2ASIRT1NSD2
SCHEMBL2112486 0.80 HTT (0.57) HTTKMT2AKDM4EALDH1A1HPGD
SCHEMBL5030912 0.79 EDNRA (0.55) HTR1AHTR3AMEN1KMT2ASIRT1
SCHEMBL8639079 0.79 POLB (0.57) HTTSIRT1NSD2KDM4EALDH1A1
SCHEMBL7969385 0.79 NPC1 (0.51) SIRT1NSD2KDM4EALDH1A1HPGD
SCHEMBL21624243 0.77 LCK (0.53) HTTCHEK1PIM1MAPK8CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
US-7410997-B2 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof NIPPON SULSAN KAISHA, LTD. (JP) 2008-08-12 US disclosed
US-7410997-B2 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof NIPPON SULSAN KAISHA, LTD. (JP) 2008-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R HTT 3989/4885CHEK1 4006/4885PIM1 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.